Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Olafsson

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Archives of Disease in Childhood|June 27, 2006
Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in childrenT Hofman, N Cranswick, P Kuna, et al.
Contact Lens & Anterior Eye : the Journal of the British Contact Lens Association|February 8, 2023
Risk associated with treatments for meibomian gland dysfunctionM S Magno, J Olafsson, M Beining, et al.
Vaccine|July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial, R R Abu-Elyazeed, T Heineman, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Archives of Disease in Childhood|June 27, 2006
Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in childrenT Hofman, N Cranswick, P Kuna, et al.
Contact Lens & Anterior Eye : the Journal of the British Contact Lens Association|February 8, 2023
Risk associated with treatments for meibomian gland dysfunctionM S Magno, J Olafsson, M Beining, et al.
Vaccine|July 16, 2013
Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial, R R Abu-Elyazeed, T Heineman, et al.
Pageof 2